The National Medical Products Administration (NMPA), which is the regulatory authority for medical products (drugs, medical devices, etc.) in the People's Republic of China, and the Ministry of Health, Labour and Welfare (MHLW) aim to further promote regulatory cooperation between the two countries while utilizing the existing cooperative relationship.
Bilateral Arrangements
People’s Republic of China (SFDA (currently NMPA))
Memorandum of Understanding (January 2009)
Symposia
[FY2021]
China and Japan Regional Joint Public Meeting on ICH
Since becoming a member of the ICH in 2017, China has taken various steps to implement the ICH guidelines.
With the ICH meeting held in June 2021 as an opportunity, a Joint Japan-China ICH Symposium was held with the aim of sharing information on the implementation status of the guidelines for Japan and China, including an overview of the discussion at the meeting, as well as efforts in each region.
Date: June 18, 2021
Location: Online